Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Kalaris Therapeutics, Inc. (KLRS) - Total Assets
Latest total assets as of September 2025: $81.17 Million USD
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) holds total assets worth $81.17 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kalaris Therapeutics, Inc. - Total Assets Trend (2018–2024)
This chart illustrates how Kalaris Therapeutics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kalaris Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Kalaris Therapeutics, Inc.'s total assets of $81.17 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Kalaris Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kalaris Therapeutics, Inc.'s current assets represent 100.0% of total assets in 2024, an increase from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 99.8% of total assets in 2024, up from 98.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kalaris Therapeutics, Inc. Competitors by Total Assets
Key competitors of Kalaris Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Kalaris Therapeutics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kalaris Therapeutics, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kalaris Therapeutics, Inc. is currently not profitable relative to its asset base.
Kalaris Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.89 | 0.16 | 29.39 |
| Quick Ratio | 12.89 | 0.16 | 29.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $72.12 Million | $ -11.62 Million | $ 349.02 Million |
Kalaris Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Kalaris Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.10 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 3456.7% |
| Total Assets | $118.55 Million |
| Market Capitalization | $13.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kalaris Therapeutics, Inc.'s assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Kalaris Therapeutics, Inc.'s assets grew by 3456.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kalaris Therapeutics, Inc. (2018–2024)
The table below shows the annual total assets of Kalaris Therapeutics, Inc. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $118.55 Million | +3456.74% |
| 2023-12-31 | $3.33 Million | -14.52% |
| 2022-12-31 | $3.90 Million | -98.64% |
| 2021-12-31 | $286.59 Million | -22.71% |
| 2020-12-31 | $370.82 Million | +165.97% |
| 2019-12-31 | $139.42 Million | +450.66% |
| 2018-12-31 | $25.32 Million | -- |